Article Text

Download PDFPDF
Current UK practices in steroid treatment of chronic lung disease
  1. Sajeev Job,
  2. Paul Clarke
  1. Neonatal Intensive Care Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK
  1. Correspondence to Dr Paul Clarke, Neonatal Intensive Care Unit, Norfolk & Norwich University Hospitals NHS Foundation Trust, Norwich NR4 7UY, UK; paul.clarke{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Chronic lung disease (CLD) remains an important cause of mortality and morbidity in preterm infants. Lung inflammation, whether of antenatal or postnatal onset, is a major factor in its pathogenesis. Corticosteroids modulate inflammation, improve lung function and reduce ventilator dependency in infants with CLD,1 yet doubts remain about longer-term efficacy and safety. The last two decades have witnessed large oscillations in steroid use to treat CLD, from high-dose protracted treatment courses to virtually zero use, and more recently back towards lower dose regimens. Current trends in the UK are unclear. We therefore conducted a national survey to determine current practices.

In the period between August and November 2014, we contacted via email or telephone a consultant neonatologist or senior specialty training …

View Full Text


  • Contributors PC: conceived and designed the study. PC and SJ: acquired and analysed the data. SJ and PC: wrote the first and final manuscript drafts, respectively. Both approved the final version. PC is guarantor.

  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.